InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-03-13 | Gilbert Cisneros(D-CA31) | house | Sale | $1,001 - $15,000 |
| 2025-10-06 | Rick Larsen(D-WA02) | house | Sale | $1,001 - $15,000 |
| 2025-08-05 | Gilbert Cisneros(D-CA31) | house | Sale | $1,001 - $15,000 |
| 2025-08-04 | Lisa McClain(R-MI09) | house | Sale | $1,001 - $15,000 |
| 2025-07-22 | Lisa McClain(R-MI09) | house | Purchase | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenues | $9.47B+2.3% | $9.26B+8.3% | $8.54B+5.7% | $8.08B+3.9% | $7.78B |
| Cost of Sales | $2.67B-1.9% | $2.72B+6.2% | $2.56B+4.4% | $2.45B+6.6% | $2.30B |
| Selling, general and administrative expenses | $2.38B+2.6% | $2.32B+7.8% | $2.15B+7.1% | $2.01B+0.4% | $2.00B |
| Research and development expenses | $698.0M+1.7% | $686.0M+11.7% | $614.0M+13.9% | $539.0M+6.1% | $508.0M |
| Amortization of intangible assets | $128.0M-9.2% | $141.0M-5.4% | $149.0M-0.7% | $150.0M-6.8% | $161.0M |
| Restructuring charges and certain acquisition and divestiture-related costs | $51.0M-3.8% | $53.0M+0.0% | $53.0M | — | — |
| Interest expense, net of capitalized interest | $222.0M-1.3% | $225.0M-5.9% | $239.0M+8.1% | $221.0M-1.3% | $224.0M |
| Other (income)/deductions––net | -$36.0M-89.5% | -$19.0M+88.1% | -$159.0M-497.5% | $40.0M-16.7% | $48.0M |
| Income before provision for taxes on income | $3.36B+7.2% | $3.13B+6.7% | $2.94B+10.5% | $2.66B+6.8% | $2.49B |
| Provision for taxes on income | $687.0M+7.8% | $637.0M+6.9% | $596.0M+9.4% | $545.0M+20.0% | $454.0M |
| Net income before allocation to noncontrolling interests | $2.67B+7.1% | $2.50B+6.7% | $2.34B+10.8% | $2.11B+3.8% | $2.03B |
| Less: Net income/(loss) attributable to noncontrolling interests | $0-100.0% | $10.0M+350.0% | -$4.0M-33.3% | -$3.0M | — |
| Net income attributable to Zoetis Inc. | $2.67B+7.5% | $2.49B+6.1% | $2.34B+10.9% | $2.11B+3.8% | $2.04B |
| Basic (in dollars per share) | $6.0M+10.2% | $5.5M+7.7% | $5.1M+12.6% | $4.5M+5.1% | $4.3M |
| Diluted (in dollars per share) | $6.0M+10.1% | $5.5M+7.9% | $5.1M+12.9% | $4.5M+5.2% | $4.3M |
| Basic (in shares) | $443.44B-2.4% | $454.20B-1.5% | $461.17B-1.6% | $468.89B-1.2% | $474.35B |
| Diluted (in shares) | $443.83B-2.4% | $454.85B-1.6% | $462.27B-1.7% | $470.38B-1.3% | $476.72B |
| Dividends declared per common share | $2.0M+13.0% | $1.8M+15.4% | $1.6M+15.3% | $1.4M+25.6% | $1.1M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Techcyte Announces $15 Million Capital Raise Led by Van Tuyl Companies to Support Growth and Path to Profitability
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Zoetis (ZTS) Sees a More Significant Dip Than Broader Market: Some Facts to Know